Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

Bibliographic Details
Main Authors:	Yu-Ting Ma, Yan Li, Li Yan, Fang Hua, Dong-Guan Wang, Guo-Ying Xu, Hong-Lan Yang, Ying-Jie Xue, Ye-Jun Qin, Dan Sha, Hao Ning, Miao-Qing Zhao, Zhi-Gang Yao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Pathology and Oncology Research
Subjects:	immunotherapy microsatellite instability immune checkpoint inhibitors urothelial carcinoma lynch syndrome PD-1/PD-L1
Online Access:	https://www.por-journal.com/articles/10.3389/pore.2023.1610989/full

Similar Items

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
by: Yu-Ting Ma, et al.
Published: (2022-10-01)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01)

Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study
by: Yu-Ting Ma, et al.
Published: (2023-11-01)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2022-06-01)

Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression
by: Youssra Salhi, et al.
Published: (2023-07-01)

Case report: A colorectal cancer patient with microsatellite instability-high and MSH2 germline mutation failed to respond to anti-PD-1 immunotherapy
by: Qun Zhang, et al.
Published: (2022-08-01)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
by: Randy F. Sweis, et al.
Published: (2018-04-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency
by: Nuran Sungu, et al.
Published: (2023-10-01)

Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan
by: Tsutomu Yoshida, et al.
Published: (2022-12-01)

Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting
by: Moran Gadot, et al.
Published: (2022-09-01)

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
by: Jason Zhu, et al.
Published: (2018-01-01)

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
by: Ding-Xin Liu, et al.
Published: (2020-01-01)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
by: Giandomenico Roviello, et al.
Published: (2021-08-01)

Maintenance immunotherapy in advanced urothelial cancer
by: María T. Bourlon, et al.
Published: (2022-07-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Role of immunotherapy in bladder cancer
by: Logan P. Rhea, et al.
Published: (2021-01-01)

Exceptional response to immunotherapy in association with radiotherapy in patient with breast metastasis from urothelial carcinoma: A case report
by: Giulia Bonfante, et al.
Published: (2021-01-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients
by: Veronika Weyerer, et al.
Published: (2021-05-01)

Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors
by: Maria Rasmussen, et al.
Published: (2023-04-01)

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
by: Zhengyang Yang, et al.
Published: (2022-09-01)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
by: Pei-Fei Liao, et al.
Published: (2023-11-01)

Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors
by: Julie Leclerc, et al.
Published: (2021-01-01)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
by: YunYi Du, et al.
Published: (2022-11-01)

Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
by: Maryam Noori, et al.
Published: (2024-01-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Lynch Syndrome: Its Impact on Urothelial Carcinoma
by: Andrea Katharina Lindner, et al.
Published: (2021-01-01)

Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma
by: Lifang Guo, et al.
Published: (2021-01-01)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
by: Grace Wakabayashi, et al.
Published: (2019-12-01)

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
by: Sonja Bergmann, et al.
Published: (2020-01-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors
by: GAN Zi-ying, TANG Hui
Published: (2022-04-01)

Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms
by: Arta M. Monjazeb, et al.
Published: (2021-02-01)

Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti–PD-1/PD-L1–Based Therapy
by: Haifeng Li, et al.
Published: (2021-08-01)

Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection
by: Enrico Munari, et al.
Published: (2022-07-01)

Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
by: MA Yinjuan, et al.
Published: (2021-06-01)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
by: Jianzheng Wang, et al.
Published: (2021-06-01)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022-04-01)

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
by: Xu Yang, et al.
Published: (2024-01-01)